Accessibility to multiple sclerosis treatment in Uruguay
References
Cristiano E, Rojas JI. Multiple sclerosis epidemiology in Latin America: an updated survey. Mult Scler J Exp Transl Clin 2017; 3(2):2055217317715050. doi: 10.1177/2055217317715050.
Paz-Zulueta M, Parás-Bravo P, Cantarero-Prieto D, Blázquez-Fernández C, Oterino-Durán A. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord 2020; 43:102162. doi: 10.1016/j.msard.2020.102162.
Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 2019; 76(5):536-41. doi:10.1001/jamaneurol.2018.4905.
Chalmer TA, Baggesen LM, Norgaard M, Koch-Henriksen N, Magyari M, Sorensen PS. Early versus later treatment start in multiple sclerosis: a register-based cohort study. Eur J Neurol 2018; 25(10):1262-e110. doi: 10.1111/ene.13692.
Fondo Nacional de Recursos. Tratamiento de la esclerosis múltiple con Interferón Beta, Acetato de Glatiramer, Fingolimod y Ocrelizumab. Normativa de cobertura. 2023. Disponible en: https://www.fnr.gub.uy/wp-content/uploads/2012/07/n_trat_escmultiple.pdf. (Consulta: 14 enero 2024).